Cargando…

ODP257 Alpelisib Treatment Associated With Severe Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer

INTRODUCTION: Alpelisib is an inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA) which was approved by US FDA to treat postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aziz, Shima, Katwal, Dilasha, James, Deirdre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Diabetes & Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629244/ http://dx.doi.org/10.1210/jendso/bvac150.704

Ejemplares similares

Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis
por: Espinosa, Luis Borges, et al.
Publicado: (2021)

SAT110 Euglycemic Diabetes Ketoacidosis Associated With Sodium-glucose Cotransporter Inhibitors: A Case Series To Raise Awareness
por: Katwal, Dilasha, et al.
Publicado: (2023)

THU259 Alpelisib-induced Diabetic Ketoacidosis: Call For A Multidisciplinary Approach
por: Kalara, Niketa, et al.
Publicado: (2023)

Alpelisib-Induced Diabetic Ketoacidosis- A Case Report
por: Rodriguez, Lisette Patricia, et al.
Publicado: (2021)

ODP173 Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin
por: Hee, Nicholas Ken Yoong, et al.
Publicado: (2022)

Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
por: Al Zeyoudi, Jawaher, et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
por: Abufaied, Mohamad, et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis
por: Nguyen, Paul, et al.
Publicado: (2021)

ODP192 Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad
por: Nievera, Karl Homer, et al.
Publicado: (2022)

ODP159 A Rare Case of Pembrolizumab Induced Diabetic Ketoacidosis
por: Durrani, Jawahar, et al.
Publicado: (2022)

ODP225 Mixed Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome with recent diagnosis of Diabetes Mellitus.
por: Adyanthaya, Sindhoora, et al.
Publicado: (2022)

ODP649 COVID-19 Induced Diabetic Ketoacidosis Which Unmasked Latent Autoimmune Diabetes In Adult
por: Alqaisi, Sura, et al.
Publicado: (2022)

ODP216 Interventional Study To Reduce The Readmission Rate In Type 1 Diabetics Hospitalized For Diabetic Ketoacidosis
por: Hashmi, Syed Salman Hamid, et al.
Publicado: (2022)

THU380 A Case Of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient With Type 2 Diabetes Mellitus And Rechallenge With SGLT2 Inhibitor
por: Sekar, Vijaykumar, et al.
Publicado: (2023)

ODP195 EUGLYCEMIC DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY IN ASSOCIATION WITH USE OF SGLT2I.
por: Vaghasia, Nishit, et al.
Publicado: (2022)

Alpelisib Induced Hyperglycemic Ketoacidosis; Broadening the Adverse Effect Profile of an Emerging Cancer Therapy
por: Prasad, Apurwa, et al.
Publicado: (2021)

ODP183 Diabetic Ketoacidosis Precipitated by Ketogenic Diet and SGLT-2 Inhibitor Use in an Individual with T2DM
por: Mason, Timothy, et al.
Publicado: (2022)

ODP628 Quality Improvement Project (QIP) On Management Of Diabetic Ketoacidosis (DKA) In Adults In A District General Hospital.
por: Haddad, Aiman, et al.
Publicado: (2022)

Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient
por: Fugere, Tyler, et al.
Publicado: (2021)

ODP175 COVID-19 Induced Euglycemic Diabetic Ketoacidosis in a Patient taking Sodium-Glucose Cotransporter-2 Inhibitors
por: Alqaisi, Sura, et al.
Publicado: (2022)

ODP231 Outcomes of Weight-based vs. Constant-based Insulin Infusion for Treatment of Diabetic Ketoacidosis in Non-ICU Patients
por: Alrifai, Nada, et al.
Publicado: (2022)

ODP182 Diabetes types and risk of severe COVID-19
por: Kazlauskaite, Rasa, et al.
Publicado: (2022)

MON-678 Worsening Diabetes Control in Breast Cancer Patients Treated with Alpelisib
por: Geier, Robert, et al.
Publicado: (2020)

PSUN257 Acute Onset Diabetes and GAD Antibody Positivity After COVID-19
por: Wilson, Jessica
Publicado: (2022)

A Case of Diabetic Keto Acidosis From Alpelisib
por: Thumma, Soumya P, et al.
Publicado: (2021)

ODP245 Syndrome of Diabetic Ketoalkalosis due to Severe Hypercortisolemia: A Case Series
por: Uwaifo, Gabriel, et al.
Publicado: (2022)

ODP260 New Type of Autoimmune Diabetes
por: Kumar, Surina, et al.
Publicado: (2022)

PSUN139 Leukemoid Reaction in Severe Diabetic Ketoacidosis: An Indicator of Severity or Predictor of Infection?
por: Sarigumba, Marion, et al.
Publicado: (2022)

ODP220 Latent Autoimmune Diabetes of Adults and PCOS - an Unusual Combination
por: Pisklakova, Alexandra, et al.
Publicado: (2022)

ODP227 Nivolumab Induced Type 1 Diabetes
por: Lim, Jonea, et al.
Publicado: (2022)

ODP180 Diabetes Apps: Do They Help Our Patients?
por: Xia, Alexander, et al.
Publicado: (2022)

ODP214 INSULIN REQUIRING DIABETES MELLITUS(IRDM) and CAD
por: Singh, Santosh
Publicado: (2022)

ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia
por: Mamtani, Raashi, et al.
Publicado: (2022)

ODP234 Proposal for an Inclusive Diabetes Education Program in Regional Schools
por: Zappala, Renata Francioni L, et al.
Publicado: (2022)

ODP202 Geriatric Type 1 Diabetes- unique management challenge
por: Patel, Toral, et al.
Publicado: (2022)

ODP184 Diabetic Postural Dizziness,Hyperlactatemia,Hyponatremia-Role of Fludrocortisone
por: Singh, Santosh
Publicado: (2022)

PSUN274 Chlorthalidone-Induced Diabetic Ketoacidosis.
por: Zafar, Rafia, et al.
Publicado: (2022)

PSUN242 Severe Hypernatremia in a patient with combined Hyperosmolar Hyperglycemic State and Diabetic Ketoacidosis
por: Batch, Jennifer, et al.
Publicado: (2022)

THU310 A Presentation Of Diabetic Ketoacidosis In Gestational Diabetes
por: Yim, Carly, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lh1mhi4uoelmf3atsmiscqnedq